Antibacterial R&D at a Crossroads: We’ve Pushed as Hard as We Can … Now We Need to Start Pulling!-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Antibacterial R&D at a Crossroads: We’ve Pushed as Hard as We Can … Now We Need to Start Pulling!

Published:2020-06-25 Issue:11 Volume:73 Page:e4451-e4453
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Rex John H¹²,Outterson Kevin³⁴

Affiliation:

1. F2G Limited, Eccles, Cheshire, United Kingdom

2. McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, Texas, USA

3. Boston University School of Law, Boston, Massachusetts, USA

4. CARB-X, Boston, Massachusetts, USA

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaa852/33679549/ciaa852.pdf

Reference39 articles.

1. An analysis of antibacterial drug development trends in the US, 1980–2019;Dheman;Clin Infect Dis,2020

2. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America;Boucher;Clin Infect Dis,2009

3. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE;Rice;J Infect Dis,2008

4. Diagnosing the decline in pharmaceutical R&D efficiency;Scannell;Nat Rev Drug Discov,2012

5. Drugs for bad bugs: confronting the challenges of antibacterial discovery;Payne;Nat Rev Drug Discov,2007

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Extracellular vesicles as therapeutics for inflammation and infection;Current Opinion in Biotechnology;2024-02

2. Pandemic preparedness—political perspectives;Sustainable Microbiology;2024-01

3. Progress and New Challenges in Combatting the Threat of Antimicrobial Resistance: Perspective From an Infectious Diseases Pharmacist;The Journal of Infectious Diseases;2023-07-24

4. Lead/Drug Discovery from Natural Resources;Molecules;2022-11-28

5. Emerging antibiotic resistance: Why we need new antibiotics!;Swiss Medical Weekly;2022-11-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3